Stockscreener 앱 받기
13.77
0.00%
0.00
시간 외 거래:
13.78
0.010
+0.07%
전일 마감가:
$13.77
열려 있는:
$13.77
하루 거래량:
2.89M
Relative Volume:
1.30
시가총액:
$3.62B
수익:
$6.16B
순이익/손실:
$246.00M
주가수익비율:
14.67
EPS:
0.9387
순현금흐름:
$708.00M
1주 성능:
+0.22%
1개월 성능:
+0.95%
6개월 성능:
+61.24%
1년 성능:
+43.44%
1일 변동 폭
$13.76
$13.79
1주일 범위
$13.75
$13.83
52주 변동 폭
$5.69
$13.83
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.77 | 3.62B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,166.51 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.61 | 599.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
274.36 | 484.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.98 | 350.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.41 | 270.68B | 54.66B | 13.58B | 16.05B | 7.0171 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-28 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
USU6836GAB42 Bond Yield and Price — BONDSCOM:USU6836GAB42 - TradingView
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Organon & Co stock hits 52-week high at 13.79 USD - Investing.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - Dealroom
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review - Yahoo Finance
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN) - Seeking Alpha
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - pharma.economictimes.indiatimes.com
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Canada
Organon & Co stock hits 52-week high at $13.78 - Investing.com India
Organon & Co stock hits 52-week high at $13.78 - investing.com
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com UK
Henlius - henlius.com
Organon earnings up next: Can drugmaker rebound after Q1 miss? - investing.com
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com South Africa
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오가논 & Co 주식 (OGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Head of Mfg & Supply |
Aug 05 '26 |
Sale |
13.57 |
14,761 |
200,307 |
18,475 |
| JULIANA P DRINANE | Officer |
Aug 05 '26 |
Proposed Sale |
13.57 |
14,761 |
200,307 |
0 |
| Holzbaur Lynette | SVP and Corporate Controller |
May 06 '26 |
Buy |
13.35 |
26,448 |
353,080 |
52,851 |
| Holzbaur Lynette | Affiliate |
May 06 '26 |
Proposed Sale |
13.35 |
26,448 |
353,080 |
0 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
17,925 |
0 |
105,265 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '26 |
Option Exercise |
0.00 |
18,513 |
0 |
96,147 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
73,494 |
| Holzbaur Lynette | SVP and Corporate Controller |
Mar 31 '26 |
Option Exercise |
0.00 |
10,967 |
0 |
28,316 |
| Morrissey Joseph T. Jr. | Interim CEO |
Mar 31 '26 |
Option Exercise |
0.00 |
24,584 |
0 |
127,907 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '26 |
Option Exercise |
0.00 |
13,431 |
0 |
34,867 |
2.71%
0.43%
자본화:
|
볼륨(24시간):